NanoNEXT

Review Article

A Review of the Ethical Frameworks in Wearable Nano Biosensors for Real-Time Monitoring of Metabolic Disorders

Archibald Danquah-Amoah [a], R. Kishore Kanna [b,*], Dominic Akwasi Bonah [c], Samson Amponsah [d]

[a] Department of Medical Laboratory Technology and Biomedical Medical Equipment Technology Accra Technical University Ghana
[b] Department of Biomedical Engineering, Jerusalem College of Engineering, Chennai-600100, Tamil Nadu, India
[c] Environmental Chemistry, Soil Science, Land Pollution Control, Accra Technical University, Department of Science Lab Technology , P. O. Box GP561, Accra, Ghana
[d] Department of Biomedical Engineering, Koforidua Technical University, 3P8P+F5F, Koforidua-Nsutam Rd, Koforidua, Ghana
*Corresponding author Email: kishorekanna007@gmail.com
DOI: https://doi.org/10.54392/nnxt2342
Received: 19-08-2023; Revised: 26-11-2023; Accepted: 05-12-2023; Published: 14-12-2023

Abstract: The healthcare environment is in the process of shifting paradigm to continuous to personalized health management, as opposed to episodic care that centres on a hospital. This revolution is fuelled by the emergence of the nano-biosensors that combine the state of art nanotechnology and bioelectronics to deliver real-time information of never seen before human health information. This review article gives a complete overview of principles, materials, fabrications and applications of wearable nano sensors. It discusses the underlying strengths of nanomaterials, i.e., being ultra-sensitive, miniaturized, and biocompatible, to enable the detection of a broad spectrum of physiological and biochemical biomarkers. The report explores the latest technology of manufacturing i.e. the electrospinning and inkjet printing and goes into the burning issue of energy consumption and offers smart solutions to counter the challenge of power consumption. It also looks at usage of these devices in the treatment of chronic illnesses, and the latest application in sophisticated systems such as brain machine interface (BMI) and prosthetics. Lastly, the technical, biological, ethical issues such as the foreign body reaction, nanotoxicity, data privacy, and the issue of equity are analysed in a critical way. The discussion ends with a review that developed mass adoption of this technology will rely mainly on progression that involves strong material science, low-power written communication, high-level data analysis, and an active ethical system.

Keywords: Biosensor, Nano, Metabolic, Healthcare

1. Introduction

Metabolic disorders are a wide grouping of disorders, which involves the alteration in the normal chemical processes in the body. This may cause the surplus or shortage of materials that are important to health by affecting degradation of amino acids, carbohydrates or lipids [1]. The most notable ones are diabetes, obesity, and cardiovascular diseases (CVDs) which form a major global health burdens and a leading cause of death and disability in the whole world. It is especially in cases with conventional diagnostic approaches to such conditions that are invasive or even less frequent and more costly. These usually include tests such as blood draws or an advanced imaging test, which only gives a single snapshot of a patient's health at a singular point in time. This reactionary strategy is not appropriate in the ever-changing, progressive nature of metabolic disease [2], where close surveillance is important to make the process more manageable and responsive to intervention [3]. Use of a non-invasive, constant health monitoring technology that includes a paradigm shift towards a more continuous health monitoring model is thus one of the most important priorities in the contemporary healthcare industry as shown in figure 1.

In this review, the author focuses on the role played by nano-biosensors in offering a solution to this important unmet need. These tools, also referred to as miniature probes with a size range of 1-100 nanometres, are designed to transduce particular biological or biochemical interactions into an electrical, optical or magnetic signal [4]. They are a revolutionary step forward in biosensing technology that has broken the paradigm of exercising traditional methods to

DOI: 10.54392/nnxt2342

embark on a new age of personalized, proactive health [5].

This report will review with critical analysis the most recent developments in nano-biosensors of metabolic disorders, the basic technology, important nanomaterials, and applications in respect to specific biomarkers [6]. It will also give a strict evaluation of the technical and ethical hurdles and it will explore future directions, especially the transformative convergence with artificial intelligence (AI) [7].



Figure 1. Overview of Nano Based Real-Time Metabolic Monitoring Healthcare Application

2. Fundamental Principles and Advanced Nanomaterials

2.1. Defining Nano-Biosensors: Components and Sensing Mechanisms

A nano-biosensor is in analytical tool with three fundamental components namely a bioreceptor, transducer and signal processing unit. A bioreceptor is a biological component, which specifically binds with an analyte of interest (e.g. glucose). The transducer then translates this particular specific biochemical interaction at an electrical, optical or mechanical signal [8]. Then the signal is amplified and then the analysis is done.

Different mechanisms of sensing are used in these devices. By monitoring the changes in electrical characteristics i.e. current or potential, electrochemical biosensors employ an alternative technique to detect biomarkers [9]. The optical biosensors, however, quantify changes in optical properties like absorbance, fluorescence and refractive index in order to measure the analytes. As an example, mechanical nano sensors (including cantilevers and nanowires) are designed to sense alterations in electrical changes, such as resistance or capacitance, induced by mechanical stress or adsorption of a target molecule.

2.2. Advanced Nanomaterials: Properties and Biomedical Relevance

High efficiency of nano-biosensors over their traditional analogues is rooted directly of unique characteristics of the nanomaterials that compose these biosensors. The major benefit comes in the form of a large surface-to-volume ratio on the nanoscale. Such a property makes an interaction with biological analytes more efficient and deep enough to sense trace amounts of biomarkers in biofluids. This is extremely important in the treatment of metabolic diseases [10], where a metabolic disease is manifested subtlety or at the early low levels of changes in the concentration of the biomarkers [11]. It is this sensitivity nano sensors have that makes the real-time detection of these conditions possible at all, which is what anchors the possibility of early diagnosis and proactive health management based on it.

2.2.1. Carbon-Based Nanomaterials

Carbon-based nanomaterials are leading the application of biosensors because they exhibit superior characteristics.

Graphene: This is a two- dimensional (2D) sheet of carbon atom, which is highly appreciated due to its immense electrical conductivity, extreme flexibility, and high surface area. The surface chemistry Graphene is easily modifiable that can be easily used to anchor biorecognition elements thereby, making it an ideal platform in the development of next-generation wearable sensing technologies [12]. It has a superior mechanical strength and chemical stability when compared to other nanomaterials hence it is a better option at long term permanent stable bio-interfaces.

Carbon Nanotubes (CNTs): CNTs are single-dimensional nanostructures that are formed based on the graphene through rolling up into a structure. CNTs have a very high electric conductivity, as well as strength. They can be made functional so that they are compatible with living matter and less likely to aggregate, their natural property preventing successful performance.

Although graphene and CNTs have similar futuristic usages in bio-related interfaces, they do exhibit a specific design limitation. Graphene shows excellent mechanical performance and chemical stability and thus it is quite suitable to maintain long lasting equipment under harsh conditions in a biological environment [13]. Whereas CNTs are characterized by extreme ballistic transport behavior as well as high density of current-carrying capacity that, at room temperature, are a hundred times higher than copper wires. This would imply that a professional design has to be dependent on the original aim of the device, i.e., graphene to maintain long-term stability and CNTs deployment in a case where final electrical superiority is the priority. This brings to the fore another aspect of a sensitive engineering choice that is more than mentioning material property.

2.2.2. Metallic Nanoparticles and Quantum Dots

Nano-biosensors also advance on the basis of metallic nanoparticles and quantum dots.

Metallic Nanoparticles There is a wide use of gold (AuNPs) and silver (AgNPs) nanoparticles that possess excellent conductivity, great surface-area-to-volume ratio, and unique plasmonic properties. They are commonly incorporated in electrochemical sensors to bring about improved performance in these sensors. AuNPs, specifically, are well recognized as highly biocompatible [14] and are applied in many medical and drug delivery instances.

Quantum Dots (QDs): They are nanocrystals of the semiconductor whose generation wavelength can be adjusted precisely by size. The latter feature renders them desirable in optical sensing applications, which include detection of minute changes in biomolecular interactions and physiological values.

2.3. The Shift to Flexible and Stretchable Platforms

Flexible and stretchable electronics are a recent major technological innovation in the area. This is significant as this innovation can be used to bridge the mechanical mismatch with the human body that rigid, traditional sensors do not take into account. These devices can be made more adaptable to a variety of situations by using materials with a lower bending stiffness: carbon-based nanomaterials or conductive polymers [15]. The step towards tissue-like electronic devices makes the least impact on the natural environment of the body and is a precondition to high patient compliance and correct and prolonged collection of the data.

3. Literature Survey

A synthesis of the recent progress about nano-biosensors in real-time monitoring of metabolic disorders is presented in the following table in terms of the important nanomaterials, sensing mechanism, and clinical relevance. What the figures show is an inexorable drift toward multiplexing, the ability to have one instrument probe a variety of intertwined biomarkers [16]. This is of particular importance to metabolic disorders, frequently comorbid and with common underlying inflammatory pathways, e.g. obesity, diabetes, and cardiovascular diseases. Creating biosensors with multiple analytes is a potential solution to the complications of the pathophysiology of these conditions by increasing the holistic and correct nature of the diagnostic.

4. Discussion

4.1. Non-Invasive Continuous Glucose Monitoring

Continuous glucose monitoring (CGM) is the most developed use of nano-biosensors in the case of metabolic disorders. The conventional glucose monitoring equipment like invasive finger-pricks is uncomfortable and only informs at spaced out intervals [23]. The use of nanomaterial-based biosensors has circumvented these shortcomings since they allow real-time non-invasive, glucose monitoring in such readily datable body fluids as sweat, tears, and saliva.

An important emerging technology in this field is very sensitive graphene-based bio-sensors. A graphene field-effect transistor was one of the devices capable of such low glucose detection limits [24]. Such high sensitivity makes possible less invasive mediums where analyte concentrations are much lower than in blood, e.g. tears and sweat. It is a paradigm shift in the care of patients. Directly addressing a human-centred issue of patient inconvenience and noncompliance is achieved by the technological capacity of the high-sensitivity nano sensors. A significant clinical implication of this technology concerns this transition to comfort, user-centric and proactive practises as opposed to hospital-centric reactive practises.

Table 1.

Reference (APA Format)	Nanomaterial(s) Used	Biomarker/Analyte Detected	Metabolic Disorder	Sensing Mechanism/Biofluid	Key Finding/Significance
[17]	Gold nanoparticles,carbon nanotubes, quantum dots	Multiple (general)	Multiple (general)	Various/Biofluids	Comprehensive review of nanomaterials in biosensing, highlighting improved sensitivity, miniaturization, and biocompatibility for early disease detection.
[18]	Silver nanoparticles, MoS2, reduced graphene oxide	Cardiac troponin I (cTnI)	Cardiovascular Disease	Electrochemical/Blood	A novel aptamer-based electrochemical sensor achieved high sensitivity and selectivity for cTnI, a key biomarker for myocardial injury.
[19]	Graphene derivatives, gold nanoparticles, metal-organic frameworks (MOFs)	Glucose	Diabetes	Electrochemical/Sweat, Interstitial Fluid	A review highlighting the critical role of nanomaterials in enhancing sensitivity, selectivity, and miniaturization of continuous glucose monitors (CGMs) for sweat-based platforms.
[20]	Gold nanoparticles, silver nanocubes, reduced graphene oxide, mesoporous graphene	Interleukin-6 (IL-6), Na+, cortisol	Inflammation/Metabolic Status	Electrochemical, SERS/Biological Samples	Review showcasing nanomaterials' use for sensitive detection of various biomarkers, including inflammatory markers, to improve non-invasive diagnosis.
[21]	Gold nanoparticles, graphene oxide	Glycated albumin (GA), Glucose	Diabetes	Electrochemical/Human Serum	A dual-mode sensor was developed to simultaneously detect both short-term (glucose) and intermediate-term (GA) diabetes markers, providing a more holistic assessment of glycemic control.
[22]	Graphene, carbon nanotubes, quantum dots, metal nanoparticles	Multiple (general)	Chronic Diseases	Various/Sweat, Saliva	Review of wearable sensors for continuous monitoring of health and disease, highlighting the role of nanomaterials in enhancing sensor performance.

4.2. Monitoring of Cardiovascular and Obesity-Related Biomarkers

Other than diabetes, nano-biosensors are also applied in the early detection and treatment of cardiovascular diseases (CVDs). Another example would be the presence of nanoparticle-based electrochemical sensors used to detect the presence of cardiac troponin I (cTnI), a critical biomarker released into the blood upon a myocardial injury [25]. Posteriorly, the electrochemical method has enabled the detection of other universal biomarkers such as C-reactive protein (CRP) which is associated with CVDs. Graphene-based devices have been used to measure the CRP levels in saliva, which opens the venue of using more accessible, non-invasive devices to diagnose the disease.

This technology is also being used to address the interrelated nature of metabolic disorders, as was the case in the interplay between obesity and chronic inflammation [26]. Nanomaterials may be employed to detect inflammatory markers and an index to indicate oxidative stress such as glutathione. Indeed, it has been established that obesity is linked to a chronic systemic inflammatory condition characterised by abnormally high levels of pro-inflammatory cytokines such as IL-6. The potential to track these common biomarkers via Nano sensors offers a multi-analytic system in terms of healthcare in which care can go beyond remedying single-condition based diagnoses to enhance the overall snapshot of metabolic health in an individual.

4.3. Therapeutic Integration and Personalized Medicine

Future of nano-biosensors will not only be to provide data but also become part of the cure. There are attempts of researchers to ensure that the output of the sensor can directly instigate a therapeutic effect in the form of closed-loop systems. Some wearable patches are developed to not only detect glucose but also allow accurate insulin delivery e.g. For example. This could also be applied to implantable sensors that accompany traditional drugs to monitor therapy on an ad-hoc basis in order to tailor dosage to individuals, such as in the case of cancer [27]. This methodology is in line with the concept of personalized medicine, with the tailoring of treatments considering real-time and individual characteristics of the patient on a physiological, cellular, or molecular level, which allows proactive interventions, leading to patient outcomes.

Whilst they have good potential, nano-biosensors have technical barriers. The main drawback is that semiconductor-based devices have inherently low-frequency noise, downgrading the signal-to-noise ratio (SNR) and limiting detection abilities. To overcome this researchers are applying novel signal amplification strategies, including rolling circle amplification (RCA) in silicon nanowire (SiNW) biosensors, in order to improve their electronic responses to record low detection limits. A second issue is the variability in the data and consistent standards of data collection practices between the different sensors and sensors and data collection practices such that the reliability and quality of data becomes a challenge to use in the clinical setting. Important concerns facing wearable and implanted nano-biosensors are the risks of lack of biocompatibility [28]. Wearable gadgets are also subject to skin irritation, allergies when materials are exposed to human leaching and chemical release/reactivity (galvanic corrosion) caused by sweat contact with electronics.

The greatest difficulty facing the implantable neural interfaces relates to FBR. This is an inflammatory reaction occasioned by the mismatch between rigid materials of the device (silicon or platinum) and the soft tissue of the nerve [29]. The FBR results in the development of a fibrous scar that surrounds the implant increasing the electrode impedance significantly and lowering the signal quality over time as a result.

This problem is actively tackled by the field through a paced design evolution. The earliest efforts were aimed at the creation of soft, flexible and tissue-like electronics to reduce mechanical force on an implant site. The following advance is that of advanced biohybrid interfaces that promote host tissue attachment through an active process [30]. Biomaterial coatings or even living cells on these interfaces nurture the survival of the neurons and minimize an FBR to the device, so that it becomes an integrated construct as part of the body rather than an external foreign one.

Continuous, stable power is a key limiting factor with wearable and implantable devices. Although there have been developments in ultra-low power electronics this technology pales into comparison with the new area of energy harvesting [31]. Scientists are designing systems able to scavenge power from ambient sources, such as motion of a wearer (piezoelectricity), ambient thermal and vibrational energy. This is a step towards self-powering, or battery free devices which is vital in the creation of fully autonomous systems that can be able to function in the long term without the necessity of heavy batteries or regular recharging.

The rise of the usage of continuous health monitoring is a serious cause of ethical and security concerns. The information provided by wearable sensors concerning heart rate, activity, and GPS location can be used to take very deep inside the person their mood, stress level and behavioural patterns. This poses major privacy risks because the information sold to third parties can be resold or in cases of post-anonymization re-identified [32]. The secrecy of the data collection method used by a large number of the devices makes the problem of the informed consent doubly complicated since users are likely to not have all the ways of data storage, processing, and sharing planned. That will require shift towards privacy-by-design strategy and strong regulatory frameworks that guarantee ethical processing of data and legal responsibility.

5. Future Scope

5.1. From Monitoring to Predictive Analytics

A major reason such convergence is the future of nano-biosensors is the association with AI and ML. I am taking the whole field beyond passive data collection into anticipating predictive health management. With the help of I models, it is possible to process large amounts of data to notice the slightest changes in physiological indicators, and to warn in advance about the emergence of symptoms [33]. It can be used to predict health occurrences like in diabetics where it can be used to predict the occurrence of hypoglycaemia or in finding signs of infectious disease early on.

An important purpose of AI will help remedy the technical constraints of Nano sensors. AI/ML can process raw sensor signals to remove background noise and to detect anomalies improving overall system reliability and accuracy driven by the hardware limitation [34]. Indicatively, a Butterworth low-pass filter can be applied to DNN to eliminate noise induced by the motion artifacts before the data are analysed. This feedback loop fusion of the software and the hardware is the direction the field is headed based in a stronger, smarter system.

5.2. Toward Ubiquitous and Personalized Healthcare

The final point of this convergence in technologies is to develop ubiquitous, individualized medical systems. Devices are next to come that can scavenge energy so they can have no battery powered existence, and are continuously available through independent power sources and therefore be truly seamless in our lives and integrated. This would enable people with actionable insights that are personalized and at the same time provide useful aggregated data to the urban planners, and the government health policy makers [35]. The implementation of such systems on a mass scale holds the potential to transform the reactive treatment-based approach to a proactive, patient-diagnostic management approach across the board, but especially to the benefit of individuals with lifestyle-related chronic conditions and of the society writ large.

6. Conclusion

Nano-biosensors are a revolutionary technology to revolutionize healthcare and represent a way forward toward personalized, proactive, real-time health management of metabolic disorders. According to the peculiarities of the advanced nanomaterials, like the high conductivity and flexibility of graphene and the biosafety of gold nanoparticles, these devices eliminate the disadvantages of conventional diagnostics technologies, which are invasive. They allow chronic, non-invasive measurement of a large number of biomarkers in easy to obtain biofluids, and increase patient compliance and comfort.

Nonetheless, the route to the wider clinical application has not been devoid of a considerable series of challenges. Technical issues include the refinement of signal stability and the prevention of noise in addition to long-term biocompatibility especially when devices are implanted. The foreign body reaction and mechanical incompatibility have been a major concern and most of these conditions are being encountered to create soft and flexible interfaces and biohybrid interfaces. Moreover, ethical and regulatory norms need to develop and adapt to serious concerns of data privacy, security and the difficulty in obtaining good informed consent in the passive data collection age.

Nevertheless, the combination of nano-biosensors with artificial intelligence is the most perspective future direction, despite these difficulties. This synergy causes the devices to go beyond being mere data collectors to smart, learned platforms that can be used to perform predictive analysis, noise reduction, and even provide therapeutic integration. By combining the latest hardware with innovative software, the revolution is on its way to a world where healthcare is no longer limited to the clinic but is the natural part of our daily lives providing ongoing continuous actionable insights that empower both individual people and clinicians.

References

[1] M. Bishnoi, Deepika, N. Mody, A. Jain, (2022). Biomedical applications of nano-biosensor. In Nanotechnology for biomedical Applications, Singapore: Springer Singapore, 219-246. https://doi.org/10.1007/978-981-16-7483-9_10

[2] N. Muhammad, L.T. Hoo, A.N. Ahmad, A. Mohamad, S. Abdullah Lim, (2021). Accuracy of biosensors as rapid diagnostic and biochemical monitoring tools for non-communicable diseases management. In Advanced Micro-and Nano-manufacturing Technologies: Applications in Biochemical and Biomedical Engineering, Singapore, 57-75. https://doi.org/10.1007/978-981-16-3645-5_3

[3] K.S.S. Sahi, S. Kaushik, (2022). Smart nanosensors for healthcare monitoring and disease detection using AIoT framework. In Nanosensors for Futuristic Smart and Intelligent Healthcare Systems, CRC Press, 387-400. https://doi.org/10.1201/9781003093534-19

[4] S. Chandna, K. Gogde, R. Kaur, V. Sagar, J. Bhaumik, (2022). Nano-biosensors for plant biomass: Concept and applications. In The role of nanoparticles in plant nutrition under soil pollution: Nanoscience in nutrient use efficiency Cham: Springer International Publishing, 199-221. https://doi.org/10.1007/978-3-030-97389-6_9

[5] S. Kaushik, V. Soni, E. Skotti, (2022). Nanosensors for futuristic smart and intelligent healthcare systems. Boca Raton, FL: CRC Press. https://doi.org/10.1201/9781003093534

[6] N. Shah, A. Badiye, N. Kapoor, R.K. Shukla, (2022). Nano-biosensors for biochemical analysis. In Nanobioanalytical Approaches to Medical Diagnostics, Woodhead Publishing, 319-343. https://doi.org/10.1016/B978-0-323-85147-3.00005-0

[7] K. Girigoswami, A. Girigoswami, A review on the role of nanosensors in detecting cellular miRNA expression in colorectal cancer. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders, 21(1) (2021) 12-26. http://dx.doi.org/10.2174/1871530320666200515115723

[8] D. Sharma, G. Teli, K. Gupta, G. Bansal, G.D. Gupta, P.A. Chawla, Nano-biosensors from agriculture to Nextgen diagnostic tools. Current Nanomaterials, 7(2) (2022) 110-138. https://doi.org/10.1007/978-3-030-39978-8_7

[9] U. Jain, S. Shakya, K. Saxena, (2021). Nano-biosensing devices detecting biomarkers of communicable and non-communicable diseases of animals. In Biosensors in agriculture: recent trends and future perspectives Cham: Springer International Publishing, 415-434. https://doi.org/10.1007/978-3-030-66165-6_19

[10] J. Singhal, S. Verma, S. Kumar, D. Mehrotra, (2021). Recent advances in nano-bio-sensing fabrication technology for the detection of oral cancer. Molecular biotechnology, 63(5), 339-362. https://doi.org/10.1007/s12033-021-00306-x

[11] S. Younis, R. Zia, N. Tahir, S.Z. Bukhari, W.S. Khan, S.Z. Bajwa, (2022). Nanosensors for animal health monitoring. In Nanosensors for smart agriculture, Elsevier. 509-529. https://doi.org/10.1016/B978-0-12-824554-5.00026-4

[12] B.N. Chopda, Y. Kaushik, M. Manchanda, S. Jain, P. Randhawa, G.B. Mohammad, (2022). Nano sensors for detection of diabetes-a review. In 2022 First International Conference on Artificial Intelligence Trends and Pattern Recognition (ICAITPR) IEEE, Hyderabad, India, 1-6. https://doi.org/10.1109/ICAITPR51569.2022.9844204

[13] S.A. El-Safty, M.A. Shenashen, (2020). Advanced nanoscale build-up sensors for daily life monitoring of diabetics. Advanced Materials Interfaces, 7(15), 2000153. https://doi.org/10.1002/admi.202000153

[14] B. Bharali, H. Chetia, J.J. Kalita, P.V. Mosahari, A.K. Chhillar, U. Bora, (2019). Engineered nanomaterials in plants: sensors, carriers, and bio imaging. In Comprehensive Analytical Chemistry, Elsevier, 87, 133-157. https://doi.org/10.1016/bs.coac.2019.09.009

[15] K.D. Lin, B.S. Lin, G.A. Lin, B.S. Lin, (2021). Design of smart peripheral blood perfusion monitoring system for diabetics. IEEE Sensors Journal, 21(8), 10167-10173. https://doi.org/10.1109/JSEN.2021.3058717

[16] M.S. Teja, T.R. Konatham, V. Muralidharan, A. Murugesan, N. Vasantha, M. Hyandavi, A Review on Biosensors for COVID-19. International Journal of Applied Pharmaceutical Sciences and Research, 7(01) (2022) 9-14.

[17] Q. Wang, X. Sun, C. Liu, C. Wang, W. Zhao, Z. Zhu, S. Ma, S. Zhang, (2023). Current development of stretchable self-powered technology based on nanomaterials toward wearable biosensors in biomedical applications. Frontiers in Bioengineering and Biotechnology, 11, 1164805. https://doi.org/10.3389/fbioe.2023.1164805

[18] J. Li, S. Zhang, L. Zhang, Y. Zhang, H. Zhang, C. Zhang, X. Xuan, M. Wang, J. Zhang, Y. Yuan, A novel graphene-based nanomaterial modified electrochemical sensor for the detection of cardiac troponin I. Frontiers in Chemistry, 9 (2021) 680593. https://doi.org/10.3389/fchem.2021.680593

[19] Tamoghna Saha, Rafael Del Caño, Kuldeep Mahato, Ernesto De la Paz, Chuanrui Chen, Shichao Ding, Lu Yin, Joseph Wang, Wearable Electrochemical Glucose Sensors in Diabetes Management: A Comprehensive Review. Chemical Reviews, 123 (2023) 7854–7889. https://doi.org/10.1021/acs.chemrev.3c00078

[20] Sumit Malik et al. Nanomaterials-based biosensor and their applications: A review, Heliyon, 9 (2023) e19929. https://doi.org/10.1016/j.heliyon.2023.e19929

[21] S. Anuthum, J. Jakmunee, K. Ounnunkad, (2023). Dual-mode electrochemical biosensor based on gold nanoparticles/two-dimensional MoWS2/graphene oxide composite for detection of glycated albumin and glucose toward advancing diabetes diagnosis. ACS Applied Bio Materials, 8(6), 5215-5228. https://doi.org/10.1021/acsabm.5c00534

[22] G. Johnson. (2023). Wearable biosensors for continuous health monitoring. European Journal for Biomedical Informatics, 23(16), 7013.

[23] M. Thanaraj, R. Rathanasamy, S.K. Jaganathan, Advancements in ultra-sensitive nanoelectronic biosensors for medical applications. Current Nanoscience, 17(5) (2021) 679-693. http://dx.doi.org/10.2174/157341371766621012114185

[24] A. Younas, Z. Yousaf, M. Rashid, N. Riaz, S. Fiaz, A. Aftab, S. Haung, (2020). Nanotechnology and plant disease diagnosis and management. In Nanoagronomy , Springer International Publishing, 101-123. https://doi.org/10.1007/978-3-030-41275-3_7

[25] J. Marrugo-Ramírez, L. Karadurmus, M.A. Aroca, E.P. Nguyen, C.D.C.C. e Silva, G. Rosati, J.F. Osma, S.A. Ozkan, A. Merkoçi, (2022). Nanomaterials-based wearable biosensors for healthcare. In Biosensors, CRC Press, 345-379.

[26] R. Arshad, I. Fatima, S. Sargazi, A. Rahdar, M. Karamzadeh-Jahromi, S. Pandey, A.M. SDiez-Pascual, M. Bilal, Novel perspectives towards RNA-based nano-theranostic approaches for cancer management. Nanomaterials, 11(12) (2021) 3330. https://doi.org/10.3390/nano11123330

[27] B. Foroutan, A.R.A. Najafabadi, Capabilities of bioinformatics tools for optimizing physicochemical features of proteins used in Nano biosensors: A short overview of the tools related to bioinformatics. Biochemistry and biophysics reports, 27 (2021) 101094. https://doi.org/10.1016/j.bbrep.2021.101094

[28] A. Tomer, R. Singh, S.A. Dwivedi, (2021). Nanotechnology for detection and diagnosis of plant diseases. In Biobased Nanotechnology for Green Applications, Springer International Publishing, 221-237. https://doi.org/10.1007/978-3-030-61985-5_8

[29] N. Hari, S. Radhakrishnan, A.J. Nair, (2020). Nanosensors as potential multisensor systems to ensure safe and quality food. In Biotechnological approaches in food adulterants, CRC press, 204-238.

[30] S. Kaul, R. Singh, S. Kamaraju, P. Suman, (2020). Changing Trends in Immunosensing Technologies and Their Commercial Aspects in Animal Health and Welfare. In Immunodiagnostic Technologies from Laboratory to Point-Of-Care Testing, Springer, Singapore, 141-161. https://doi.org/10.1007/978-981-15-5823-8_8

[31] R. Munusami, M. Ramasamy, (2022). Multiplexed biosensors for efficient diagnosis of the clinical conditions toward Health management. In Miniaturized biosensing devices: fabrication and applications, Springer, Nature Singapore, 205-225. https://doi.org/10.1007/978-981-16-9897-2_9

[32] S. Kaushik, (2022). Nanosensor technology for smart intelligent agriculture. In Agricultural Biotechnology, CRC Press, 267-299.

[33] B. Kuswandi, (2020). Real-time quality assessment of fruits and vegetables: sensing approaches. In Sensor-Based Quality Assessment Systems for Fruits and Vegetables, Apple Academic Press, 1-30. https://doi.org/10.1201/9781003084174

[34] P.M. Gotovtsev, Y.M. Parunova, C.G. Antipova, G.U. Badranova, T.E. Grigoriev, D.S. Boljshin, M.V. Vishnevskaya, E.A. Konov, K.I. Lukanina, S.N. Chvalun, A.N. Reshetilov, (2021). Self-powered implantable biosensors: A review of recent advancements and future perspectives. Macro, Micro, and Nano-Biosensors: Potential Applications and Possible Limitations, 399-410. https://doi.org/10.1007/978-3-030-55490-3_20

[35] V. Rohatgi, N.V. Challagulla, R.N. Pudake, (2021). Volatile organic compounds (VOCs) sensors for stress management in crops. In Biosensors in Agriculture: Recent Trends and Future Perspectives, Springer International Publishing, 81-95. https://doi.org/10.1007/978-3-030-66165-6_5

Funding

The author's did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Data Availability

No datasets were generated or analyzed during the current study. All data supporting the findings of this study are included in the manuscript.

Conflict of interest

The Author's declares that there is no conflict of interest anywhere.

Does this article screened for similarity?

Yes

About the License